Funding
Turn ideas into impact
Show Me
Due: November 17, 2026
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
Type
Grant
Source
Federal
Opp Number
PAR-25-268
Due: November 17, 2026
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
Type
Grant
Source
Federal
Opp Number
PAR-25-158
Due: November 18, 2026
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
Type
Grant
Source
Federal
Opp Number
PAR-25-369
Due: November 18, 2026
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
Type
Grant
Source
Federal
Opp Number
PAR-25-371
Due: November 19, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer’s Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Type
Cooperative Agreement
Source
Federal
Opp Number
PAR-25-226
Due: November 19, 2026
DoW Toxic Exposures Investigator Initiated Research Award
Type
Grant
Source
Federal
Opp Number
HT942526TERPIIRA
Due: November 19, 2026
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Type
Cooperative Agreement
Source
Federal
Opp Number
PAR-25-052
Due: November 19, 2026
DoW Toxic Exposures Translational Research Award
Type
Grant
Source
Federal
Opp Number
HT942526TERPTRA
Due: November 19, 2026
DoW Toxic Exposures Clinical Trial Award
Type
Grant
Source
Federal
Opp Number
HT942526TERPCTA
Submit your funding opportunity.
Do you have a grant, incentive, funding competition, or other funding source to share?